Strik, Herwig Matthias

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T11:08:46Z"],["dc.date.available","2018-11-07T11:08:46Z"],["dc.date.issued","2008"],["dc.format.extent","1115"],["dc.identifier.isi","000261695800218"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52865"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Duke Univ Press"],["dc.publisher.place","Durham"],["dc.relation.conference","8th Congress of the European-Association-for-Neuro-Oncology (EANO)"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","1522-8517"],["dc.title","LONG TERM STABILIZATION OF LEPTOMENINGEAL AND SOLID CNS METASTASES FROM BREAST CANCER WITH COMBINED INTRATHECAL LIPOSOMAL ARA-C AND SYSTEMIC TEMOZOLOMIDE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","711"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Neuroscience Research"],["dc.bibliographiccitation.lastpage","717"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Baron, Nina"],["dc.contributor.author","Deuster, Oliver"],["dc.contributor.author","Noelker, Carmen"],["dc.contributor.author","Stueer, Carsten"],["dc.contributor.author","Strik, Herwig"],["dc.contributor.author","Schaller, Carlo"],["dc.contributor.author","Dodel, Richard"],["dc.contributor.author","Meyer, Bernhard"],["dc.contributor.author","Bacher, Michael"],["dc.date.accessioned","2018-11-07T08:56:51Z"],["dc.date.available","2018-11-07T08:56:51Z"],["dc.date.issued","2011"],["dc.description.abstract","Macrophage migration inhibitory factor (MIF) is a protein that is overexpressed in many tumors, such as colon and prostate cancer, melanoma, and glioblastoma multi-forme (GBM). In its function as a cytokine, MIF induces angiogenesis, promotes cell cycle progression, and inhibits apoptosis. Recently, the molecular signal transduction has been specified: MIF has been found to be a ligand to the CD74/CD44-receptor complex and to activate the ERK1/2 MAPK cascade. In addition MIF binds to the chemokine receptors CXCR2 and CXCR4. This effects an integrin-dependent leukocyte arrest and mediates leukocyte chemotaxis. Recent work has described a clearer role of MIF in GBM tumor cell lines. The current study used human primary GBM cells. We show that inhibition of MIF with ISO-1, an inhibitor of the D-dopachrome tautomerase site of MIF, reduced the growth rate of primary GBM cells in a dose-dependent manner, and in addition ISO-1 increased protein expression of MIF and its receptors CD74, CXCR2, and CXCR4 in vitro but decreased expression of CD44. Furthermore, hypoxia as cell stressor increases the protein expression of MIF in primary GBM cells. These results underscore the importance of MIF in GBM and show that MIF and its receptors may be a promising target for the treatment of malignant gliomas. (C) 2011 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/jnr.22595"],["dc.identifier.isi","000288513300009"],["dc.identifier.pmid","21360573"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23249"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0360-4012"],["dc.title","Role of Macrophage Migration Inhibitory Factor in Primary Glioblastoma Multiforme Cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Rock, Hans"],["dc.contributor.author","Kallenberg, Kai"],["dc.date.accessioned","2018-11-07T09:10:23Z"],["dc.date.available","2018-11-07T09:10:23Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009801393"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26475"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","Tegwondo-CCNU: A novel combination of protracted, near-continuous temozolomide and CCNU with activity in recurrent malignant gliomas."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","251"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Magnetic Resonance Imaging"],["dc.bibliographiccitation.lastpage","258"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Strik, Claudia"],["dc.contributor.author","Klose, Uwe"],["dc.contributor.author","Erb, Michael"],["dc.contributor.author","Strik, Herwig"],["dc.contributor.author","Grodd, Wolfgang"],["dc.date.accessioned","2021-12-08T12:30:36Z"],["dc.date.available","2021-12-08T12:30:36Z"],["dc.date.issued","2002"],["dc.identifier.doi","10.1002/jmri.10084"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/96492"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-476"],["dc.relation.eissn","1522-2586"],["dc.relation.issn","1053-1807"],["dc.rights.uri","http://doi.wiley.com/10.1002/tdm_license_1.1"],["dc.title","Intracranial oscillations of cerebrospinal fluid and blood flows: Analysis with magnetic resonance imaging"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","226"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Folia Neuropathologica"],["dc.bibliographiccitation.lastpage","233"],["dc.bibliographiccitation.volume","52"],["dc.contributor.author","Kallenberg, Kai"],["dc.contributor.author","Goldmann, Torben"],["dc.contributor.author","Menke, Jan"],["dc.contributor.author","Strik, Herwig"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Frahm, Jens"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Knauth, Michael"],["dc.date.accessioned","2018-11-07T09:45:46Z"],["dc.date.available","2018-11-07T09:45:46Z"],["dc.date.issued","2014"],["dc.description.abstract","Introduction: Malignant brain tumors tend to migration and invasion of surrounding brain tissue. Histopathological studies reported malignant cells in macroscopically unsuspicious parenchyma (normal appearing white matter - NAWM) remote from the tumor localization. In early stages, diffuse interneural infiltration with changes of the apparent diffusion coefficient (ADC) and fractional anisotropy (FA) is hypothesized. Material and methods: Patients' ADC and FA values from NAWM of the hemisphere contralateral to a malignant glioma were compared to age- and sex-matched normal controls. Results: Apparent diffusion coefficient levels of the entire contra lateral hemisphere revealed a significant increase and a decrease of FA levels. An even more pronounced ADC increase was found in a region mirroring the glioma location. Conclusions: In patients with previously untreated anaplastic astrocytoma or glioblastoma, an increase of the ADC and a reduction of FA were found in the brain parenchyma of the hemisphere contralateral to the tumor localization. In the absence of visible MRI abnormalities, this may be an early indicator of microstructural changes of the NAWM attributed to malignant brain tumor."],["dc.description.sponsorship","Volkswagen Stiftung [ZN1635, ZN 2193]"],["dc.identifier.doi","10.5114/fn.2014.45563"],["dc.identifier.isi","000342712000002"],["dc.identifier.pmid","25310733"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34702"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1509-572X"],["dc.relation.issn","1641-4640"],["dc.title","Abnormalities in the normal appearing white matter of the cerebral hemisphere contralateral to a malignant brain tumor detected by diffusion tensor imaging"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","37"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","42"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Stoll, Monika"],["dc.contributor.author","Meyermann, Richard"],["dc.date.accessioned","2018-11-07T10:52:02Z"],["dc.date.available","2018-11-07T10:52:02Z"],["dc.date.issued","2004"],["dc.description.abstract","Background: Immune escape is one prerequisite for the formation of neoplasms that is reflected by the pattern of immune cell infiltration. Abundant monocytic infiltration without apparent phagocytic activity is well known in human gliomas, while other types of human intracranial tumours have not yet been investigated. Materials and Methods: We analysed LCA-positive lymphocytes and CD68-positive macrophages/ microglia by immunohistochemistry in 67 intracranial neoplasms: 18 glioblastomas (GBM), 14 primitive neuroectodermal tumours and medulloblastomas (PNET), metastases of 9 adenocarcinomas and of 8 malignant melanomas, and 18 benign meningiomas. Results: Levels of monocytic infiltration in GBM and adenocarcinomas were higher than in PNET and meningiomas. Lymphocytes were rare in all tested tumours. No differences were found between all malignant neoplasms and benign meningiomas and between primary intracranial and metastatic tumours. Conclusion: Malignancy or primary intracranial origin seem not to be major determinants of immune cell infiltration. Different patterns of cytokine production may explain the differences in single tumour entities."],["dc.identifier.isi","000189271900005"],["dc.identifier.pmid","15015573"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49026"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Int Inst Anticancer Research"],["dc.relation.issn","0250-7005"],["dc.title","Immune cell infiltration of intrinsic and metastatic intracranial tumours"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Strik, H. M."],["dc.contributor.author","Bock, C.-H."],["dc.contributor.author","Kallenberg, K."],["dc.date.accessioned","2018-11-07T08:43:11Z"],["dc.date.available","2018-11-07T08:43:11Z"],["dc.date.issued","2010"],["dc.identifier.isi","000208852000233"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19898"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.title","Near-continuous temozolomide and low-dose weekly CCNU: A novel chemotherapy regimen with activity in malignant gliomas resistant to dose-dense temozolomide alone."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","314"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Acta Neurologica Belgica"],["dc.bibliographiccitation.lastpage","320"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Moldrich, G."],["dc.contributor.author","Lange, P."],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T08:35:56Z"],["dc.date.available","2018-11-07T08:35:56Z"],["dc.date.issued","2010"],["dc.description.abstract","Objective: the diagnostic impact of carcinoembryonic antigen (CEA) was evaluated in serum and CSF of cancer and control patients. Methods: 97 analyses of CEA in CSF and serum from 83 cancer patients were compared with 41 cases without malignancy. CEA diffusion dynamics were evaluated with IgA CSF/serum quotients (Q 10). Intrathecal synthesis of CEA was analysed both by calculating an index Q CEA/Q IgA and within the IgA-diagram. Results: in 73 samples without synthesis of IgA or CEA, both quotients correlated well with a mean Q CEA/Q IgA of 1.1 (95% CI 0.97-1.2). The Q CEA/Q IgA was significantly higher in metastasizing adenocarcinomas than in controls or other malignancies. In leptomeningeal disease from adenocarcinoma, Q CEA/Q IgA was significantly higher than in controls, while patients with CNS and/or bone metastases had intermediate values. The sensitivity to detect leptomeningeal disease was 91% and 69% for brain metastases. Q CEA/Q IgA and CEA synthesis assessed with the IgA diagram were equally sensitive. Conclusions: evaluation of CEA in the IgA diagram is feasible and of clinical value. The consideration of intrathecal CEA synthesis correlates better with the clinical status than absolute CSF-CEA or the correlation with albumin."],["dc.identifier.isi","000286162900007"],["dc.identifier.pmid","21305861"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18195"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Acta Medica Belgica"],["dc.relation.issn","0300-9009"],["dc.title","Carcinoembryonic Antigen in the CSF of Cancer Patients - the value of intrathecal synthesis and correlation with IgA-diffusion dynamics"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1195"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","1200"],["dc.bibliographiccitation.volume","250"],["dc.contributor.author","Pohl, Marcus"],["dc.contributor.author","Rockstroh, Günter"],["dc.contributor.author","Rückriem, Stefan"],["dc.contributor.author","Mehrholz, Jan"],["dc.contributor.author","Pause, Max"],["dc.contributor.author","Koch, Rainer"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T10:35:51Z"],["dc.date.available","2018-11-07T10:35:51Z"],["dc.date.issued","2003"],["dc.description.abstract","Continuous intrathecal administration of baclofen with implanted programmable pump systems is recommended in the treatment of severe spasticity of cerebral origin. Prior to pump implantation, a baclofen bolus test (BBT) is used to assess the effectiveness of intrathecal baclofen using clinical scales such as the Modified Ashworth Scale (MAS). In the literature, the time and period of maximum effect of a bolus dose of intrathecally administered baclofen in patients with cerebral spasticity is variously reported. The aim of the study was, therefore, to reveal the time course of the effect of a BBT on severe cerebral spasticity by the use of a recently described spasticity measurement method. Spasticity in knee joints of 13 patients with severe cerebral spasticity was repeatedly assessed using the MAS and also continuously recorded by the measurement of force under circular fibreglass casts. Force was recorded as net-torque by multiplying the force by the distance between sensor and joint axis, thus allowing inter-individual comparison. Half-hour time integrals (TI) of net-torque were determined 9 hours before and 22 hours after intrathecal baclofen administration. Post-BBT half-hour time integrals (TI+0, TI+0.5, to TI+22) were compared with the mean of 17 pre-BBT half-hour time integrals ((TI) over bar (-9 to-1)). Significantly lower post-BBT half-hour time integrals compared with (TI) over bar (-9 to -1) were found between TI+2 and TI+8 (Dunnett adjusted p < 0.05). The median lowest TI after BBT of the 13 patients was TI+4. The lowest mean MAS scores were found 4 hours after BBT. The findings suggest that the greatest effect of BBT on cerebral spasticity occurs between 2 and 8.5 hours, with a maximal effect at 4 hours after intrathecal baclofen injection. Clinical scales used to determine the effect of BBT should thus be carried out during this period - ideally at 4 hours after baclofen injection."],["dc.identifier.doi","10.1007/s00415-003-0178-1"],["dc.identifier.isi","000186231900009"],["dc.identifier.pmid","14586601"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45189"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0340-5354"],["dc.title","Time course of the effect of a bolus dose of intrathecal baclofen on severe cerebral spasticity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","295"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Experimental and Therapeutic Medicine"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Brunotte, J."],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T08:58:36Z"],["dc.date.available","2018-11-07T08:58:36Z"],["dc.date.issued","2011"],["dc.description.abstract","Erythropoietin (EPO) is used to treat anemia in neoplastic disease. EPO also exerts neuroprotective effects on neuronal cells, making a prophylactic use against the neurocognitive effects of radiochemotherapy probable. However, EPO/EPO-receptor (EPOR) signalling has been also detected in glioblastoma cells. Data collected in vitro and in vivo show conflicting results on the effect of EPO on malignant gliomas. The association between EPO and EPOR expression and the prognosis of human glioblastomas was analyzed. Probes of human glioblastomas with complete documentation of clinical course and treatment were assessed by immunohistochemistry for the expression of EPO and EPOR (n=80). Using univariate and multivariate survival analysis, the association with age, gender, radiation, chemotherapy and extent of resection was determined. High levels of EPOR were correlated with a median survival advantage of 7 months (p<0.01). By univariate, but not multivariate, analysis, high levels of EPO and EPOR were associated with a significant prolongation of 7 months median survival when compared to low levels of both molecules. In patients treated with radiochemotherapy adjuvant to surgery, the median survival was 6.5 months longer in patients with high levels of EPOR (p<0.04). According to previous studies, longer patient survival is associated with EPOR expression. Therefore, EPO appears to be safe for the treatment of anemia in glioblastoma patients. However, a prophylactic use, i.e., for neuroprotection, is not recommended in light of the functional studies described in the literature."],["dc.identifier.doi","10.3892/etm.2011.198"],["dc.identifier.isi","000287822700019"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23680"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Spandidos Publ Ltd"],["dc.relation.issn","1792-0981"],["dc.title","High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]